KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-cash Items: 2011-2019

Historic Non-cash Items for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Mar 2019 value amounting to $2.6 million.

  • Supernus Pharmaceuticals' Non-cash Items rose 7.07% to $2.6 million in Q1 2019 from the same period last year, while for Mar 2019 it was $2.6 million, marking a year-over-year increase of 7.07%. This contributed to the annual value of $57.2 million for FY2018, which is 47.27% down from last year.
  • Supernus Pharmaceuticals' Non-cash Items amounted to $2.6 million in Q1 2019, which was down 95.45% from $57.2 million recorded in Q4 2018.
  • In the past 5 years, Supernus Pharmaceuticals' Non-cash Items ranged from a high of $108.5 million in Q4 2017 and a low of $856,008 during Q2 2015.
  • In the last 3 years, Supernus Pharmaceuticals' Non-cash Items had a median value of $2.2 million in 2017 and averaged $20.1 million.
  • In the last 5 years, Supernus Pharmaceuticals' Non-cash Items soared by 530.00% in 2015 and then tumbled by 47.27% in 2018.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Non-cash Items stood at $12.6 million in 2015, then spiked by 333.91% to $54.7 million in 2016, then spiked by 98.49% to $108.5 million in 2017, then tumbled by 47.27% to $57.2 million in 2018, then climbed by 7.07% to $2.6 million in 2019.
  • Its Non-cash Items was $2.6 million in Q1 2019, compared to $57.2 million in Q4 2018 and $1.9 million in Q3 2018.